Works matching IS 2160763X AND DT 2020 AND VI 9 AND IP 5

Results: 12

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 552, doi. 10.1002/cpdd.840

By:

Roosendaal, Jeroen;
Rosing, Hilde;
Beijnen, Jos H.

Publication type:

Article

Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design).

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 610, doi. 10.1002/cpdd.813

By:

Hung, Noelyn Anne;
Costa, Fernando Guillermo;
Hung, Cheung‐Tak;
Rosenberg, Mónica Esther

Publication type:

Article

Pharmacokinetics of Gepotidacin in Renal Impairment.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 560, doi. 10.1002/cpdd.807

By:

Hossain, Mohammad;
Tiffany, Courtney;
Raychaudhuri, Aparna;
Nguyen, Dung;
Tai, Guoying;
Alcorn, Harry;
Preston, Richard A.;
Marbury, Thomas;
Dumont, Etienne

Publication type:

Article

Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 573, doi. 10.1002/cpdd.806

By:

Lv, Yuan;
Luo, Bin‐yu;
LaBadie, Robert R.;
Zhu, Hua;
Feng, Yan;
Ernst, Cynthia;
Crownover, Penelope H.;
Liang, Yali;
Zhao, Qinying

Publication type:

Article

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF<sup>V600</sup> Mutation–Positive Malignancies.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 651, doi. 10.1002/cpdd.788

By:

Zhang, Weijiang;
McIntyre, Christine;
Riehl, Todd;
Forbes, Harper;
Bertran, Enric;
Choi, Hye Jin;
Lee, Dae Ho;
Lee, Jeeyun

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 547, doi. 10.1002/cpdd.679
Publication type:: Article

Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 629, doi. 10.1002/cpdd.768

By:

Tsai, Max;
Case, Michael;
Ardayfio, Paul;
Hochstetler, Helen;
Wilbraham, Darren

Publication type:

Article

Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 602, doi. 10.1002/cpdd.761

By:

Wang, Meng;
Zhou, Wenjia;
Zhang, Quanying;
Zong, Shunlin;
Lv, Chengzhe

Publication type:

Article

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 639, doi. 10.1002/cpdd.750

By:

Nafziger, Anne N.;
Arscott, Kelly A.;
Cochrane, Kristina;
Skobieranda, Franck;
Burt, David A.;
Fossler, Michael J.

Publication type:

Article

Open‐Label, Randomized, Single‐Dose, 2‐Period, 2‐Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 621, doi. 10.1002/cpdd.743

By:

Du, Ping;
Li, Pengfei;
Liu, Hongchuan;
Zhao, Rui;
Zhao, Zhixia;
Yu, Weiyue;
Zhou, Xin;
Liu, Lihong

Publication type:

Article

Comparison of In Vitro and In Vivo Percutaneous Absorption Across Human Skin Using BAY1003803 Formulated as Ointment and Cream.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 582, doi. 10.1002/cpdd.736

By:

Günther, Clemens;
Kowal, Kristin;
Schmidt, Timm;
Jambrecina, Alen;
Toner, Frank;
Nave, Rüdiger

Publication type:

Article

Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 593, doi. 10.1002/cpdd.765

By:

Fan, Lin;
Zhang, Lizhi;
Zheng, Hongquan;
Cheng, Junlin;
Hu, Yunfang;
Liu, Jianghui;
Fan, Hongwei

Publication type:

Article